AstraZeneca (AZN)
Quick facts
| Ticker | AZN (NASDAQ) |
|---|
Marketed products
- Farxiga · Immunology · revenue 6300
Farxiga works by blocking the SGLT2 protein in the kidneys, reducing glucose reabsorption and promoting its excretion in the urine. - Tagrisso · Oncology · revenue 5800
Osimertinib is a kinase inhibitor of the epidermal growth factor receptor (EGFR) that binds irreversibly to mutant forms of EGFR. - Ultomiris · Cardiovascular · revenue 5100
Ultomiris blocks the action of Complement C5 to prevent inflammation and damage to red blood cells. - Imfinzi · Oncology · revenue 4900
Imfinzi works by blocking the PD-L1 protein, allowing the immune system to recognize and attack cancer cells. - Calquence · Oncology · revenue 3100
Calquence works by blocking the activity of the BTK enzyme, which is essential for the activation and survival of B cells. - Pulmicort Respules · Immunology · revenue 2800
- Lynparza · Oncology · revenue 2600
Lynparza blocks the repair of DNA damage in cancer cells by inhibiting the enzyme PARP. - Fasenra · Immunology · revenue 1800
Fasenra works by binding to the interleukin-5 receptor on eosinophils, triggering their destruction. - Opsumit · Metabolic · revenue 1181.0
Opsumit works by blocking the action of endothelin-1, a protein that causes blood vessels to constrict and increase blood pressure. - Brilinta · Cardiovascular · revenue 1100
- Prilosec · Gastroenterology · revenue 1041.0
Irreversibly inhibits the hydrogen-potassium ATPase (proton pump) in gastric parietal cells, potently suppressing stomach acid secretion. - Tezspire · Respiratory · revenue 800
Tezspire blocks the action of Thymic Stromal Lymphopoietin (TSLP), a protein that triggers inflammation in the airways. - Beyfortus · Infectious Disease · revenue 800
BEYFORTUS is a monoclonal antibody that targets RSV. - Saphnelo · Immunology · revenue 700
Saphnelo blocks the action of interferon alpha/beta, a protein that triggers an immune response. - Imjudo · Oncology · revenue 400
Tremelimumab-actl binds to CTLA-4, blocking its interaction with CD80 and CD86, thereby enhancing T-cell activation and reducing tumor growth. - Lumoxiti · Oncology · revenue 205
- Acalabrutinib capsule · Oncology
Acalabrutinib is a selective inhibitor of Bruton's tyrosine kinase (BTK) that blocks B-cell proliferation and survival signaling in hematologic malignancies. - Aclidinium bromide and formoterol
- Aclidinium bromide/formoterol fumarate combination · Respiratory/Pulmonology
Aclidinium bromide and formoterol fumarate work together as a long-acting anticholinergic and long-acting beta-2 agonist to relax airway smooth muscle and improve airflow in chronic obstructive pulmonary disease. - Albuterol and budesonide inhalation aerosol
- Endep · Neuroscience
- Anastrazole · Oncology
- Arimidex · Oncology
Anastrozole selectively inhibits aromatase enzyme, suppressing estrogen biosynthesis in postmenopausal breast cancer. - SAPHNELO · Immunology
- Anoro® Ellipta® · Respiratory / Pulmonology
Anoro Ellipta combines a long-acting beta-2 agonist and a long-acting muscarinic antagonist to relax airway smooth muscle and improve airflow in chronic obstructive pulmonary disease. - Strensiq · Bone
Strensiq works by replacing the deficient tissue-nonspecific alkaline phosphatase enzyme in patients with hypophosphatasia. - Tracleer · Immunology
- Brilinta · Cardiovascular
- Budesonide-Formoterol treatment · Respiratory/Pulmonology
Budesonide-formoterol combines a corticosteroid that reduces airway inflammation with a long-acting beta-2 agonist that relaxes airway smooth muscle to improve breathing. - Budesonide/formoterol Turbuhaler · Respiratory
Budesonide reduces airway inflammation via glucocorticoid receptor activation, while formoterol dilates airways by stimulating beta-2 adrenergic receptors. - budesonide/formoterol Turbuhaler 320/9µg · Respiratory
Budesonide reduces airway inflammation via glucocorticoid receptor activation, while formoterol dilates airways by stimulating beta-2 adrenergic receptors. - Budesonide/Glycopyrronium/Formoterol Fumarate · Respiratory/Pulmonology
This triple-combination inhaler delivers a corticosteroid (budesonide) to reduce airway inflammation, a long-acting beta-2 agonist (formoterol) to dilate airways, and an anticholinergic (glycopyrronium) to further relax airway smooth muscle. - Budesonide inhalation suspension · Respiratory/Pulmonology
Budesonide is a corticosteroid that reduces inflammation in the airways by binding to glucocorticoid receptors and suppressing inflammatory mediator production. - Byetta · Metabolic
Byetta works by activating the glucagon-like peptide 1 receptor, which helps regulate blood sugar levels. - Ciclesonide nasal spray + placebo Azelastine · Allergy/Immunology
Ciclesonide is an intranasal corticosteroid that reduces airway inflammation and mucus production to relieve nasal allergy symptoms. - CILGAVIMAB · Infectious Disease
- Conventional Best Asthma Therapy · Respiratory / Pulmonology
Conventional best asthma therapy typically combines inhaled corticosteroids with long-acting beta-2 agonists to reduce airway inflammation and improve bronchodilation. - conventional treatment for schizophrenia
- DAPA · Metabolic
- dapagliflozin and saxagliptin
Phase 3 pipeline
- Abiraterone + Prednisolone/Prednisone · Oncology
Abiraterone inhibits CYP17A1 to block androgen synthesis, while prednisolone/prednisone suppresses ACTH-driven adrenal compensation and provides anti-inflammatory effects. - Abraxane + carboplatin · Oncology
Abraxane (paclitaxel albumin-bound nanoparticles) stabilizes microtubules to halt cell division, while carboplatin creates DNA crosslinks to prevent replication, together providing synergistic cytotoxic effects against cancer cells. - ABT-143 · Oncology
ABT-143 is a bispecific antibody that simultaneously engages two distinct immune checkpoints to enhance anti-tumor T-cell responses. - ABT-335 · Cardiovascular
ABT-335 is a selective peroxisome proliferator-activated receptor delta (PPARδ) agonist that modulates lipid and glucose metabolism. - ABT-335 and rosuvastatin calcium · Cardiovascular
ABT-335 (fenofibrate) reduces triglycerides and raises HDL cholesterol by activating peroxisome proliferator-activated receptor alpha (PPARα), while rosuvastatin calcium lowers LDL cholesterol by inhibiting HMG-CoA reductase. - ABT-335 plus rosuvastatin · Cardiovascular
ABT-335 (fenofibrate analog) combined with rosuvastatin reduces triglycerides and LDL cholesterol through dual lipid-lowering pathways. - AC2993 · Endocrinology
AC2993 is a dual GLP-1/GIP receptor agonist that activates both glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide receptors to improve glycemic control and promote weight loss. - Aclidinium Bromide 200 µg · Respiratory / Pulmonology
Aclidinium bromide is a long-acting muscarinic antagonist that blocks M3 receptors in airway smooth muscle to prevent bronchoconstriction and improve airflow. - Aclidinium Bromide 400 µg · Respiratory
Aclidinium bromide is a muscarinic M3 receptor antagonist that blocks acetylcholine signaling in airway smooth muscle, causing bronchodilation. - Active Comparator: Olaparib tablets · Oncology
Olaparib inhibits poly(ADP-ribose) polymerase (PARP) enzymes, preventing DNA repair in cancer cells and causing cell death, particularly in BRCA-mutant tumors. - adequate mood stabilizer · Psychiatry
This drug stabilizes mood by modulating neurotransmitter activity. - albuterol (Ventolin) · Respiratory
Albuterol is a beta-2 adrenergic receptor agonist that works by relaxing bronchial muscles and increasing air flow to the lungs. - Anastozole (Arimidex) · Oncology
Anastrozole is a non-steroidal aromatase inhibitor that blocks the conversion of androgens to estrogen in postmenopausal women with hormone receptor-positive breast cancer. - Anastrazole (Arimidex) · Oncology
Anastrozole is a non-steroidal aromatase inhibitor that blocks the conversion of androgens to estrogen in postmenopausal women with hormone receptor-positive breast cancer. - ARIMIDEX (anastrazole) · Oncology
Anastrozole is a non-steroidal aromatase inhibitor that blocks the conversion of androgens to estrogen in postmenopausal women. - arimidex dummy · Oncology
Arimidex is an aromatase inhibitor that blocks the enzyme responsible for converting androgens to estrogens. - AS MDI
AS MDI is a metered-dose inhaler formulation that delivers an active pharmaceutical agent directly to the respiratory tract for local and/or systemic therapeutic effect. - AZD0120 · Oncology
AZD0120 is a selective inhibitor of fibroblast growth factor receptor 1 (FGFR1) that blocks aberrant signaling in cancer cells dependent on FGFR1 activation. - AZD0486 · Oncology
AZD0486 is a selective inhibitor of the mechanistic target of rapamycin complex 1 (mTORC1) that suppresses protein synthesis and cell proliferation in cancer cells. - AZD0585 · Diabetes
AZD0585 is a selective activator of the glucokinase enzyme that enhances glucose sensing and insulin secretion in pancreatic beta cells. - AZD0780 · Neurology
AZD0780 is a selective GABA-A receptor positive allosteric modulator that enhances inhibitory neurotransmission in the central nervous system. - AZD0901 · Cardiovascular / Pulmonary
AZD0901 is a selective activator of the soluble guanylate cyclase (sGC) enzyme that increases intracellular cGMP levels to promote vasodilation and reduce fibrosis. - AZD5335 · Oncology
AZD5335 is a selective inhibitor of fibroblast growth factor receptor 1 (FGFR1) that blocks aberrant FGFR signaling in cancer cells. - AZD7442 · Infectious Disease / Virology
AZD7442 is a combination of two monoclonal antibodies that bind to the SARS-CoV-2 spike protein to neutralize the virus and provide passive immunity. - AZD9291 Dosing · Oncology
AZD9291 is a third-generation EGFR tyrosine kinase inhibitor that irreversibly binds to and inhibits mutant EGFR, including T790M resistance mutations, while sparing wild-type EGFR. - AZD9833 · Oncology
AZD9833 is an oral selective estrogen receptor degrader (SERD) that binds to and degrades the estrogen receptor, blocking estrogen-driven cancer cell growth. - Baxdrostat and dapagliflozin · Cardiovascular, Diabetes
Baxdrostat inhibits aldosterone synthase to reduce aldosterone production, while dapagliflozin inhibits SGLT2 to increase urinary glucose excretion, together addressing both hypertension/heart failure and glycemic control. - Baxdrostat/dapagliflozin · Cardiovascular, Nephrology
Baxdrostat inhibits aldosterone synthase to reduce aldosterone production, while dapagliflozin inhibits SGLT2 to increase urinary glucose excretion and reduce sodium reabsorption. - Benralizumab Arm A · Immunology
Benralizumab is a monoclonal antibody that binds to the IL-5 receptor alpha on eosinophils and basophils, leading to their depletion and reduction of eosinophilic inflammation. - Benralizumab Arm B · Immunology / Respiratory
Benralizumab is a monoclonal antibody that binds to the IL-5 receptor alpha on eosinophils and basophils, leading to their depletion and reduced airway inflammation. - Benralizumab Arm C · Immunology / Respiratory
Benralizumab is a monoclonal antibody that binds to the IL-5 receptor alpha on eosinophils and basophils, leading to their depletion and reduction of eosinophilic inflammation. - Benralizumab (Medi-563) · Immunology / Respiratory
Benralizumab is a monoclonal antibody that binds to the IL-5 receptor alpha on eosinophils and basophils, leading to their depletion and reduction of eosinophilic inflammation. - beta-II-agonist, inhale steroid · Respiratory / Pulmonology
This combination therapy relaxes airway smooth muscle via beta-2 adrenergic stimulation while simultaneously reducing airway inflammation through inhaled corticosteroid activity. - Biological: Experimental: Tezepelumab · Immunology / Respiratory / Dermatology
Tezepelumab is a monoclonal antibody that blocks thymic stromal lymphopoietin (TSLP), a key upstream cytokine in type 2 inflammation. - budesonide bid + terbutaline 'as needed' · Respiratory / Pulmonology
Budesonide reduces airway inflammation via glucocorticoid receptor activation, while terbutaline rapidly relaxes airway smooth muscle via beta-2 adrenergic stimulation. - Budesonide CFC · Respiratory/Pulmonology
Budesonide is a corticosteroid that suppresses inflammatory and immune responses by binding to glucocorticoid receptors in the lungs. - Budesonide/formoterol pMDI · Respiratory/Pulmonology
Budesonide/formoterol combines an inhaled corticosteroid that reduces airway inflammation with a long-acting beta-2 agonist that relaxes airway smooth muscle. - Budesonide HFA · Respiratory/Pulmonology
Budesonide is a corticosteroid that reduces inflammation in the airways by binding to glucocorticoid receptors and suppressing inflammatory mediator production. - Budesonide HFA pMDI · Respiratory/Pulmonology
Budesonide is a corticosteroid that reduces inflammation in the airways by binding to glucocorticoid receptors and suppressing inflammatory mediator production. - Budesonide pMDI · Respiratory / Pulmonology
Budesonide is a corticosteroid that reduces inflammation in the airways by binding to glucocorticoid receptors and suppressing inflammatory mediator production.
Competitive intelligence
For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors: